AI in Life Sciences Market by Offerings, Applications, Tools, and End Users

AI in life sciences market to reach USD 69.34 billion by 2031, at a CAGR of 26.3% The AI ​​in life sciences market is expected to grow rapidly, reaching USD 69.34 billion by 2031, from USD 21.58 billion in 2026, at a CAGR of 26.3%. This proliferation is being driven by advanced AI architectures that help optimize clinical trials and accelerate drug development through data integration. North America leads with strong research networks and regulatory support. End-to-end solutions dominate the offering, reflecting the move towards unified AI platforms. Clinical applications are showing solid growth, increasing the efficiency of clinical trials and the adoption of precision medicine. SEO Keywords: AI in life sciences, drug development, clinical trials, healthcare data analysis.

AI in the life sciences market

DUBLIN, July 1, 2026 (Globe Newswire) — “AI in Life Sciences Market by Products, Applications, Tools and End Users – Global Forecast to 2031” has been added. ResearchAndMarkets.com Offerings.

The AI ​​in life sciences market is projected to reach USD 69.34 billion by 2031, from USD 21.58 billion in 2026, at a CAGR of 26.3% during the forecast period. This rapid growth is being driven by the trend toward data-oriented, agent-based AI architectures, facilitating the transition from traditional analytics to autonomous systems. These advances will have a major impact on clinical trial optimization, real-world evidence collection, and post-market monitoring, overcoming the challenges posed by large, fragmented datasets.

The introduction of cloud-based services integrated with AI technology allows life sciences companies to integrate diverse data sources, from medical and genomics data to patient-specific information, to enable predictive modeling and accelerate drug development. AI agents automate complex tasks such as literature searches, hypothesis formulation, and patient segmentation, enhancing operational efficiency and innovation.

Oracle Corporation (USA) launched the Oracle Life Sciences AI Data Platform in January 2026 to integrate over 129 million de-identified medical records with generative AI to accelerate research and clinical trials. Similarly, IQVIA Holdings Inc. (USA) introduced AI agents in June 2025 to streamline workflows for clinical and commercial operations such as target identification and clinical data analysis.

Regionally, North America leads the global AI market in life sciences, supported by advanced research networks, high levels of digitization, and significant investments in biotechnology and pharmaceutical innovation. Synergies between universities, hospitals, and technology companies will facilitate rapid adoption of AI. Additionally, a favorable regulatory environment and rapid adoption of advanced analytics in drug discovery and clinical trials have strengthened the region’s leadership position. Europe is the second largest market, driven by government and industry interest in AI technology and data privacy compliant AI products.

In terms of offerings, the market is segmented into end-to-end solutions, niche/point solutions, AI technologies, and services. In 2025, end-to-end solutions captured the largest market share due to increased demand for integrated platforms that support data ingestion, model building, validation, and deployment across the life sciences value chain. These comprehensive solutions increase efficiency from target identification to clinical and commercial levels. Enterprises now prefer full-stack AI platforms over standalone software for their scalability, compliance, and cross-functional collaboration capabilities.

This change is consistent with a broader trend toward enterprise-level AI implementation, which requires consistent, reproducible, and auditable processes for research, development, and clinical trials. For example, in October 2025, expert.ai launched an AI-powered solution to optimize clinical trial design and research workflows. In June 2025, ArisGlobal (USA) globally deployed the LifeSphere NavaX AI platform to automate the analysis of approximately 350,000 safety incidents annually.

The market is also segmented by application into clinical and non-clinical applications, with the clinical segment expected to grow the fastest. This growth is being driven by the increasing use of AI to improve the patient experience, optimize clinical trials, and advance precision medicine through real-time data analysis. AI-powered software is improving patient enrollment, trial management, and protocol optimization, shortening trial duration and increasing success rates. The growing trend towards patient-centric, decentralized clinical trials is further driving the adoption of AI, as IQVIA has deployed more than 150 AI agents by March 2026 and is used by 19 of the top 20 pharmaceutical companies.

Key attributes:

Main topics covered:

4 Market trends

• driver

  • Rapidly increasing demand for accelerating drug discovery and optimizing R&D pipelines

  • Expanding partnerships across industries

  • Expanding the application of AI in clinical trial design, patient recruitment, and operational efficiency

  • Increasing availability of large biomedical datasets and advances in computing infrastructure

  • Government support policies, funding initiatives and regulatory frameworks

• assignment

  • Low data fragmentation and interoperability deficiencies

  • Talent shortages and organizational readiness

• opportunity

  • Generative AI and foundational models for de novo drug design

  • Increasing attention to rare disease treatment

  • Growing demand for highly precise and personalized medicine

  • Integrating AI in academic research institutions and government-sponsored biomedical innovation programs

• restraints

  • Data privacy and cybersecurity concerns

  • Algorithm bias and clinician lack of trust

  • High implementation costs, technical complexity, and integration challenges with legacy IT systems

17 Company Profile

• NVIDIA Corporation

• Illumina Co., Ltd.

• Tempus AI Co., Ltd.

• recursion

• Dassault Systèmes SE

• Schrödinger Co., Ltd.

• Data for Cure Co., Ltd.

• Microsoft Corporation

• in silico medicine

• Eurofins Discovery

• Benevolentai Limited

• Orkin

• Patai

• Idoc Medical Co., Ltd.

• Qure.AI

• deep genomics

• Sophia Genetics SA

• Unlearn.AI

• barge genomics

• Synthio Lab Co., Ltd.

• biooptimus

• Karion Bio

• Counterforce health status

• promise bio

For more information on this report, please visit https://www.researchandmarkets.com/r/advc70.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment